LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension

NCT01373086 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension

Interventions

DRUG: LFF269
DRUG: Eplerenone
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals